#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating older adults need current evidence on cannabis’ effects on cognitive function and neurodegeneration, as seniors increasingly use cannabis for pain and other conditions without clear safety data in this population. Understanding how cannabis affects the aging brain directly impacts prescribing decisions and patient counseling about potential risks versus benefits in geriatric care. This research helps clinicians move beyond outdated assumptions and provide evidence-based guidance as cannabis use grows among their older patient populations.
# Clinical Summary The aging brain presents distinct neurobiological vulnerabilities that warrant careful reconsideration of cannabis safety and efficacy in older adults. Age-related changes in cannabinoid receptor density, altered pharmacokinetics, and increased susceptibility to cognitive and balance impairment mean that dosing strategies and product formulations effective in younger populations may not translate safely to geriatric patients. Clinicians should recognize that the sparse literature on cannabis in older adults limits evidence-based prescribing recommendations, necessitating lower starting doses, slower titration, and heightened monitoring for drug interactions with common polypharmacy in this population. Fall risk, delirium, and exacerbation of existing cognitive decline represent serious but potentially preventable adverse effects if age-appropriate protocols are established. For practitioners considering cannabis as a therapeutic option in aging patients with chronic pain, insomnia, or other conditions, individualized risk-benefit assessment guided by age-specific pharmacology rather than extrapolation from younger cohorts is essential to safe and effective clinical practice.
“What we’re seeing in our aging populations is that cannabinoid sensitivity increases with age due to changes in receptor density and metabolism, which means the dosing strategies we use for younger patients can produce unexpected effects in seniors, and this fundamentally changes how I approach treatment in anyone over 65.”
🧠 While emerging preclinical research suggests cannabinoids may have neuroprotective properties relevant to aging-related cognitive decline, the clinical evidence base remains sparse and is complicated by decades of limited research availability, heterogeneous study designs, and the difficulty of isolating cannabis effects from confounding factors like concurrent medications, comorbidities, and variable product composition. Older adults present particular challenges for cannabis use given age-related changes in drug metabolism, increased polypharmacy, and heightened vulnerability to cognitive and fall-related adverse effects, yet many patients may be self-treating age-related conditions without medical guidance. The rescheduling of cannabis at the federal level may accelerate clinical research and clarify which cannabinoid formulations and dosages might benefit specific geriatric populations, but providers should not assume efficacy based on mechanistic plausibility alone. In current practice, clinicians should engage older patients who use or are considering cannabis in
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: